Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos commences Phase IIa rheumatoid arthritis study
GLPG0634 is a novel Janus kinase 1 (JAK1) inhibitor being developed to treat multiple autoimmune diseases. Galapagos chief scientific officer Piet Wigerinck said the proof of concept study
GLPG0634 is a novel Janus kinase 1 (JAK1) inhibitor being developed to treat multiple autoimmune diseases. Galapagos chief scientific officer Piet Wigerinck said the proof of concept study
The new methods will produce high-purity populations of neural stem cells (NSC) from hpSC and their therapeutically valuable derivatives at a low cost. The method is capable of
ABH’s wholly owned subsidiary, Angel Biomedical Ltd (ABL) will take ownership of the manufacturing plant. The 6,500ft² facility comprises one large Grade C clean room, two smaller grade
Verified Clinical Trials is a fully web based clinical research database registry tool designed specifically to enhance the quality of both early and late phase trials. Target Health
North America Dermatology vice president Jean-Christophe May said, "Stiefel is dedicated to meeting the needs of patients and dermatologists and we believe Fabior Foam will be an important
The milestone follows the development and delivery of a prototype formulation of an Ironwood candidate meeting pre-specified attributes under the agreement signed to license Acuform technology signed in
The generic version of Pfizer’s Lipitor is indicated to prevent cardiovascular disease and hypercholesterolemia. Mylan CEO Heather Bresch said, "Mylan’s launch of Atorvastatin Calcium Tablets will help to
The Quad is a complete single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate. Gilead HIV therapeutics and development operations senior vice president Andrew Cheng said,
The system is built on a platform which consists of intuitive controls that require minimal training to operate. Viztek sales vice president Steve Deaton said, "It’s the first
Adcetris, which is an antibody-drug conjugate (ADC) directed to CD30, has not been approved for use in CTCL. The trial enrolled 17 CTCL patients, which include 16 mycosis